Extensively drug resistant tuberculosis in Mali: A case report

Bassirou Diarra; Yacouba Toloba; Bakary Konate; Moumine Sanogo; Antieme Combo Georges Togo; Fatimata Camara; Gaoussou Berthe; Dianguina Soumaré; Bocar Baya; Drissa Goita; Yeya Dit Sadio Sarro; Mamoudou Maiga; Michael Belson; Susan Orsega; Sounkalo Dao; Robert L. Murphy; Sophia Siddiqui; Bouke C. De Jong; Seydou Doumbia; Souleymane Diallo

doi:10.1186/s13104-017-2890-4

Extensively drug resistant tuberculosis in Mali: A case report

Bassirou Diarra^*, Yacouba Toloba, Bakary Konate, Moumine Sanogo, Antieme Combo Georges Togo, Fatimata Camara, Gaoussou Berthe, Dianguina Soumaré, Bocar Baya, Drissa Goita, Yeya Dit Sadio Sarro, Mamoudou Maiga, Michael Belson, Susan Orsega, Sounkalo Dao, Robert L. Murphy, Sophia Siddiqui, Bouke C. De Jong, Seydou Doumbia, Souleymane Diallo

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: Drug resistant tuberculosis presents a major public health challenge. Case presentation: We present here the first two patients diagnosed with extensively drug resistant tuberculosis in Bamako, Mali. Genotypic findings suggest possible nosocomial transmission from the first patient to the second one, resulting in superinfection of the second patient. After being diagnosed with extensively drug resistant tuberculosis in August 2016, the patients only started receiving appropriate treatment 10 months later. Conclusion: The identification of these patients highlights the need for improved diagnostic and treatment algorithms for better surveillance and management of drug resistance in Mali. In the interest of these as well as future patients suffering from resistant tuberculosis, all steps recommended for programmatic management of drug resistant tuberculosis must be urgently prioritized in order to strengthen the multidrug resistant tuberculosis program.

Original language	English (US)
Article number	561
Journal	BMC Research Notes
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s13104-017-2890-4
State	Published - Nov 6 2017

Keywords

Bamako
Mali
Treatment
XDR-TB

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13104-017-2890-4

Cite this

Diarra, B., Toloba, Y., Konate, B., Sanogo, M., Togo, A. C. G., Camara, F., Berthe, G., Soumaré, D., Baya, B., Goita, D., Sarro, Y. D. S., Maiga, M., Belson, M., Orsega, S., Dao, S., Murphy, R. L., Siddiqui, S., De Jong, B. C., Doumbia, S., & Diallo, S. (2017). Extensively drug resistant tuberculosis in Mali: A case report. BMC Research Notes, 10(1), [561]. https://doi.org/10.1186/s13104-017-2890-4

Diarra, Bassirou ; Toloba, Yacouba ; Konate, Bakary ; Sanogo, Moumine ; Togo, Antieme Combo Georges ; Camara, Fatimata ; Berthe, Gaoussou ; Soumaré, Dianguina ; Baya, Bocar ; Goita, Drissa ; Sarro, Yeya Dit Sadio ; Maiga, Mamoudou ; Belson, Michael ; Orsega, Susan ; Dao, Sounkalo ; Murphy, Robert L. ; Siddiqui, Sophia ; De Jong, Bouke C. ; Doumbia, Seydou ; Diallo, Souleymane. / Extensively drug resistant tuberculosis in Mali : A case report. In: BMC Research Notes. 2017 ; Vol. 10, No. 1.

@article{688eddfadcc9462b80ce183df041bf24,

title = "Extensively drug resistant tuberculosis in Mali: A case report",

abstract = "Background: Drug resistant tuberculosis presents a major public health challenge. Case presentation: We present here the first two patients diagnosed with extensively drug resistant tuberculosis in Bamako, Mali. Genotypic findings suggest possible nosocomial transmission from the first patient to the second one, resulting in superinfection of the second patient. After being diagnosed with extensively drug resistant tuberculosis in August 2016, the patients only started receiving appropriate treatment 10 months later. Conclusion: The identification of these patients highlights the need for improved diagnostic and treatment algorithms for better surveillance and management of drug resistance in Mali. In the interest of these as well as future patients suffering from resistant tuberculosis, all steps recommended for programmatic management of drug resistant tuberculosis must be urgently prioritized in order to strengthen the multidrug resistant tuberculosis program.",

keywords = "Bamako, Mali, Treatment, XDR-TB",

author = "Bassirou Diarra and Yacouba Toloba and Bakary Konate and Moumine Sanogo and Togo, {Antieme Combo Georges} and Fatimata Camara and Gaoussou Berthe and Dianguina Soumar{\'e} and Bocar Baya and Drissa Goita and Sarro, {Yeya Dit Sadio} and Mamoudou Maiga and Michael Belson and Susan Orsega and Sounkalo Dao and Murphy, {Robert L.} and Sophia Siddiqui and {De Jong}, {Bouke C.} and Seydou Doumbia and Souleymane Diallo",

note = "Funding Information: MDR: multidrug resistant; XDR: extensively drug resistance; WHO: World Health Organization; DST: drug susceptibility testing; RR: resistance to rifampicin; UCRC: University Clinical Research Center; BSL-3: biosafety level 3; UTH: University Teaching Hospital of Point-G; ITM: Institute of Tropical Medicine; DR-TB: drug resistant-tuberculosis; USTTB: University of Sciences, Techniques and Technologies of Bamako; TB: tuberculosis; R: rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol; S: streptomycin; K: kanamycin; O: ofloxacin; Et: ethionamide; HIV: human immunodeficiency virus; NTM: non-tuberculous mycobacteria; Mtbc: Mycobacterium tuberculosis complex; AFB: acid fast bacilli; MTB T1/T4: Mycobacterium tuberculosis T family 1 and 4; MIRU-VNTR: mycobacterial interspersed repetitive units, variable number of tandem repeats; WT: wild type; NTP: National TB Program; DGF: Global Drug Facility; Bdq: bedaquiline; Cfz: clofazimine; Dlm: delamanid; Lzd: linezolid; PAS: para acid salicylic; MUT: mutation; MGIT: mycobacterium growth incubator tube; BD: Becton–Dickinson; MD: Maryland; NIAID/NIH: National Institutes of Allergy and Infectious Diseases, National Institutes of Health; USA: United States of America; AST: antimycobacterial susceptibility testing; SIRE: streptomycin, isoniazid, rifampicin, ethambutol; PMDT: programmatic management of drug-resistant tuberculosis; LPA: Line Probe Assay; NRL: national reference laboratory; IRB: institutional review board. Funding Information: The study in which context the XDR-TB patients were identified was conducted at the University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali, and was partially funded by the USTTB through NIH/R01 grant R01AI110386, the North-western University (Chicago, IL, USA) through ACTG U01AI069471. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US. Government. B.D. was supported by a TDR fellowship, TIMS ID B40072, the special programme for research and training in tropical diseases, co-sponsored by UNICEF, UNDP, World Bank and WHO. Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = nov,

day = "6",

doi = "10.1186/s13104-017-2890-4",

language = "English (US)",

volume = "10",

journal = "BMC Research Notes",

issn = "1756-0500",

publisher = "BioMed Central",

number = "1",

}

Diarra, B, Toloba, Y, Konate, B, Sanogo, M, Togo, ACG, Camara, F, Berthe, G, Soumaré, D, Baya, B, Goita, D, Sarro, YDS, Maiga, M, Belson, M, Orsega, S, Dao, S, Murphy, RL, Siddiqui, S, De Jong, BC, Doumbia, S & Diallo, S 2017, 'Extensively drug resistant tuberculosis in Mali: A case report', BMC Research Notes, vol. 10, no. 1, 561. https://doi.org/10.1186/s13104-017-2890-4

Extensively drug resistant tuberculosis in Mali : A case report. / Diarra, Bassirou; Toloba, Yacouba; Konate, Bakary; Sanogo, Moumine; Togo, Antieme Combo Georges; Camara, Fatimata; Berthe, Gaoussou; Soumaré, Dianguina; Baya, Bocar; Goita, Drissa; Sarro, Yeya Dit Sadio; Maiga, Mamoudou; Belson, Michael; Orsega, Susan; Dao, Sounkalo; Murphy, Robert L.; Siddiqui, Sophia; De Jong, Bouke C.; Doumbia, Seydou; Diallo, Souleymane.

In: BMC Research Notes, Vol. 10, No. 1, 561, 06.11.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Extensively drug resistant tuberculosis in Mali

T2 - A case report

AU - Diarra, Bassirou

AU - Toloba, Yacouba

AU - Konate, Bakary

AU - Sanogo, Moumine

AU - Togo, Antieme Combo Georges

AU - Camara, Fatimata

AU - Berthe, Gaoussou

AU - Soumaré, Dianguina

AU - Baya, Bocar

AU - Goita, Drissa

AU - Sarro, Yeya Dit Sadio

AU - Maiga, Mamoudou

AU - Belson, Michael

AU - Orsega, Susan

AU - Dao, Sounkalo

AU - Murphy, Robert L.

AU - Siddiqui, Sophia

AU - De Jong, Bouke C.

AU - Doumbia, Seydou

AU - Diallo, Souleymane

N1 - Funding Information: MDR: multidrug resistant; XDR: extensively drug resistance; WHO: World Health Organization; DST: drug susceptibility testing; RR: resistance to rifampicin; UCRC: University Clinical Research Center; BSL-3: biosafety level 3; UTH: University Teaching Hospital of Point-G; ITM: Institute of Tropical Medicine; DR-TB: drug resistant-tuberculosis; USTTB: University of Sciences, Techniques and Technologies of Bamako; TB: tuberculosis; R: rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol; S: streptomycin; K: kanamycin; O: ofloxacin; Et: ethionamide; HIV: human immunodeficiency virus; NTM: non-tuberculous mycobacteria; Mtbc: Mycobacterium tuberculosis complex; AFB: acid fast bacilli; MTB T1/T4: Mycobacterium tuberculosis T family 1 and 4; MIRU-VNTR: mycobacterial interspersed repetitive units, variable number of tandem repeats; WT: wild type; NTP: National TB Program; DGF: Global Drug Facility; Bdq: bedaquiline; Cfz: clofazimine; Dlm: delamanid; Lzd: linezolid; PAS: para acid salicylic; MUT: mutation; MGIT: mycobacterium growth incubator tube; BD: Becton–Dickinson; MD: Maryland; NIAID/NIH: National Institutes of Allergy and Infectious Diseases, National Institutes of Health; USA: United States of America; AST: antimycobacterial susceptibility testing; SIRE: streptomycin, isoniazid, rifampicin, ethambutol; PMDT: programmatic management of drug-resistant tuberculosis; LPA: Line Probe Assay; NRL: national reference laboratory; IRB: institutional review board. Funding Information: The study in which context the XDR-TB patients were identified was conducted at the University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali, and was partially funded by the USTTB through NIH/R01 grant R01AI110386, the North-western University (Chicago, IL, USA) through ACTG U01AI069471. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US. Government. B.D. was supported by a TDR fellowship, TIMS ID B40072, the special programme for research and training in tropical diseases, co-sponsored by UNICEF, UNDP, World Bank and WHO. Publisher Copyright: © 2017 The Author(s).

PY - 2017/11/6

Y1 - 2017/11/6

N2 - Background: Drug resistant tuberculosis presents a major public health challenge. Case presentation: We present here the first two patients diagnosed with extensively drug resistant tuberculosis in Bamako, Mali. Genotypic findings suggest possible nosocomial transmission from the first patient to the second one, resulting in superinfection of the second patient. After being diagnosed with extensively drug resistant tuberculosis in August 2016, the patients only started receiving appropriate treatment 10 months later. Conclusion: The identification of these patients highlights the need for improved diagnostic and treatment algorithms for better surveillance and management of drug resistance in Mali. In the interest of these as well as future patients suffering from resistant tuberculosis, all steps recommended for programmatic management of drug resistant tuberculosis must be urgently prioritized in order to strengthen the multidrug resistant tuberculosis program.

AB - Background: Drug resistant tuberculosis presents a major public health challenge. Case presentation: We present here the first two patients diagnosed with extensively drug resistant tuberculosis in Bamako, Mali. Genotypic findings suggest possible nosocomial transmission from the first patient to the second one, resulting in superinfection of the second patient. After being diagnosed with extensively drug resistant tuberculosis in August 2016, the patients only started receiving appropriate treatment 10 months later. Conclusion: The identification of these patients highlights the need for improved diagnostic and treatment algorithms for better surveillance and management of drug resistance in Mali. In the interest of these as well as future patients suffering from resistant tuberculosis, all steps recommended for programmatic management of drug resistant tuberculosis must be urgently prioritized in order to strengthen the multidrug resistant tuberculosis program.

KW - Bamako

KW - Mali

KW - Treatment

KW - XDR-TB

UR - http://www.scopus.com/inward/record.url?scp=85032884281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032884281&partnerID=8YFLogxK

U2 - 10.1186/s13104-017-2890-4

DO - 10.1186/s13104-017-2890-4

M3 - Article

C2 - 29110699

AN - SCOPUS:85032884281

VL - 10

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

IS - 1

M1 - 561

ER -

Extensively drug resistant tuberculosis in Mali: A case report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this